JPX · 4572.T
Carna Biosciences, Inc.
¥363-¥6 (-1.63%)
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
Loading market information…
JPX · 4596.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kubota Pharmaceutical Holdings Co., Ltd.’s next earnings report is currently expected on Nov 13, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kubota Pharmaceutical Holdings Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kubota Pharmaceutical Holdings Co., Ltd., an international entity established in Tokyo, Japan, in 2002, focuses on the creation and advancement of a diverse range of pharmaceutical treatments and medical devices. A primary asset in their development pipeline is emixustat hydrochloride, a drug currently undergoing Phase III clinical trials for Stargardt disease and Phase II trials for proliferative diabetic retinopathy. Beyond its pharmaceutical endeavors, the company is also innovating in medical technology, specifically with a patient-centric ophthalmology suite designed for remote retinal monitoring. This advanced suite features both miniature, home-use optical coherence tomography (OCT) devices and high-resolution OCT technology adapted from NASA. Furthermore, Kubota Pharmaceutical Holdings is developing a wearable device aimed at controlling myopia.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
KEEP COMPARING
¥363-¥6 (-1.63%)
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
¥1,952-¥8 (-0.41%)
Sapporo Clinical Laboratory Inc.’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
¥559¥0 (0.0%)
Kringle Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.56% below the high.
¥64-¥2 (-3.03%)
Ribomic Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
¥215+¥1 (+0.47%)
Trans Genic Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
¥59-¥2 (-3.28%)
D. Western Therapeutics Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.85% below the high.
¥502-¥3 (-0.59%)
Sincere Co. Ltd.’s quoted price sits in the upper half of its reported 52-week range, 9.71% below the high.
¥506-¥11 (-2.13%)
MRT Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.19% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
